SAN FRANCISCO, Jan. 31, 2011 /PRNewswire/ — DNA Direct, a
wholly owned subsidiary of Medco Health Solutions, Inc. (NYSE:
MHS) and a provider of guidance and decision support for
genomic medicine, today announced four new health plan clients that
are implementing DNA Direct’s Policy & Benefit Support Program
for molecular diagnostic and genetic tests. The program enables
payors to determine coverage for more than 800 molecular diagnostic
and genetic tests and provides real time access to the DNA Direct
team of clinical experts for clinical guidance on more than 2,000
tests available today.
(Logo: http://photos.prnewswire.com/prnh/20100609/MEDCOLOGO)
Qualchoice of Arkansas, Inc., and Capital District Physicians
Health Plan, based in New York, are the first regional plans to
implement the program. DNA Direct also provides case review support
utilizing its team of genetic experts to provide health plans with
on demand coverage guidance. AultCare, based in Ohio, and Bluegrass
Family Health, based in Kentucky, are implementing the case review
service of the program.
“Molecular diagnostic and genetic testing represents a
multi-billion dollar market and is growing at a rapid pace,” said
Ryan Phelan, Founder & President of DNA Direct. “Due to the
increasing number of genetic tests coming on the market, there is
confusion among physicians, patients, and payors about which tests
are clinically appropriate. We are working with innovative health
plans that want to get ahead of the curve and implement an
effective strategy to provide the necessary clinical guidance and
support for providers and patients.”
There are more than 2,000 diseases for which molecular
diagnostic and genetic tests are available today, with more than
300 tests becoming available each year. DNA Direct’s Policy &
Benefi
‘/>”/>
